Biologic Therapy for Osteoarthritis in Tempe, AZ

Tempe epidemiology first — then the SKU

10.7% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. CDC PLACES (2023, crude) estimates 7.2% of adults in Tempe have diagnosed diabetes — 4.8 points below the U.S. 12% figure. Population 184,118. The useful question is not “do you have a warehouse on our street?” — it is whether receiving, IFUs, and JF documentation are ready before the first application of osteoarthritis biologic therapy.

What breaks first: photos, lots, or the LCD

• Adult arthritis here is 16.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 10.7% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Arizona.
• Arizona is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• PRP is autologous and not an HCT/P 361 allograft, but payers in JF still expect diagnosis-driven documentation. A 1-minute spin does not replace a medically necessary indication or a procedure note.

City rate, state belt, federal LCD — keep the grains

Three grains, kept separate on purpose. City: Census 184,118 and CDC PLACES crude rates. State: Arizona Department of Health Services, Diabetes Belt not in the core list. Federal: 21 CFR 1271 and Noridian Healthcare Solutions LCDs. CDC PLACES (2023, crude) estimates 7.2% of adults in Tempe have diagnosed diabetes — 4.8 points below the U.S. 12% figure.

A practical checklist for Tempe